In cardiovascular and renal outcome trials, GLP-1 agonists have consistently shown reductions in major adverse cardiovascular outcomes (MACE) and reduced risk of renal failure in patients with T2DM [128,129,130,131]. This evidence concerns the gene GCG and type 2 diabetes mellitus.